Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
Rani Therapeutics (Nasdaq: RANI) announced on October 23, 2025 the appointments of Abraham “Abe” Bassan and Vasudev Bailey, Ph.D., to its Board of Directors and the departures of Andrew Farquharson and Maulik Nanavaty.
The company highlighted strategic value from its clinical-stage pipeline and a recent collaboration with Chugai. Rani also closed a previously announced private placement expected to raise approximately $60.3 million, led by Samsara BioCapital with participation from Anomaly, RA Capital, Invus, Special Situations Funds and executive chairman Mir Imran.
Rani Therapeutics (Nasdaq: RANI) ha annunciato il 23 ottobre 2025 le nomine di Abraham “Abe” Bassan e Vasudev Bailey, Ph.D., nel suo Consiglio di Amministrazione e le dimissioni di Andrew Farquharson e Maulik Nanavaty.
L'azienda ha evidenziato il valore strategico del proprio portafoglio clinico e una recente collaborazione con Chugai. Rani ha anche chiuso una collocazione privata precedentemente annunciata che si prevede possa assicurare circa $60.3 million, guidata da Samsara BioCapital con la partecipazione di Anomaly, RA Capital, Invus, Special Situations Funds e il presidente esecutivo Mir Imran.
Rani Therapeutics (Nasdaq: RANI) anunció el 23 de octubre de 2025 los nombramientos de Abraham “Abe” Bassan y Vasudev Bailey, Ph.D., en su Junta Directiva y las salidas de Andrew Farquharson y Maulik Nanavaty.
La compañía destacó el valor estratégico de su cartera en etapas clínicas y una colaboración reciente con Chugai. Rani también cerró una colocación privada anunciada previamente que se espera genere aproximadamente $60.3 million, liderada por Samsara BioCapital con la participación de Anomaly, RA Capital, Invus, Special Situations Funds y el presidente ejecutivo Mir Imran.
Rani Therapeutics (Nasdaq: RANI)는 2025년 10월 23일에 Abraham “Abe” Bassan과 Vasudev Bailey, Ph.D.를 이사회에 임명하고 Andrew Farquharson과 Maulik Nanavaty의 이탈을 발표했다.
회사는 임상 단계 파이프라인의 전략적 가치와 최근 Chugai와의 협력을 강조했다. 또한 Rani는 앞서 발표된 비공개 배정을 마감했고 약 $60.3 million를 조달할 예정이다. 이는 Samsara BioCapital가 주도하고 Anomaly, RA Capital, Invus, Special Situations Funds 및 회장 Mir Imran이 참여했다.
Rani Therapeutics (Nasdaq : RANI) a annoncé le 23 octobre 2025 les nominations d'Abraham “Abe” Bassan et Vasudev Bailey, Ph.D., au conseil d'administration et les départs d'Andrew Farquharson et Maulik Nanavaty.
L'entreprise a souligné la valeur stratégique de son portefeuille en phase clinique et une collaboration récente avec Chugai. Rani a également clôturé une placement privé annoncé précédemment visant à lever environ $60.3 million, dirigé par Samsara BioCapital avec la participation d'Anomaly, RA Capital, Invus, Special Situations Funds et le président exécutif Mir Imran.
Rani Therapeutics (Nasdaq: RANI) kündigte am 23. Oktober 2025 die Ernennung von Abraham “Abe” Bassan und Vasudev Bailey, Ph.D., in den Vorstand an und die Abgänge von Andrew Farquharson und Maulik Nanavaty.
Das Unternehmen hob den strategischen Wert seiner klinischen Pipeline und eine jüngste Zusammenarbeit mit Chugai hervor. Rani hat außerdem eine zuvor angekündigte Private-Placement-Transaktion abgeschlossen, von der erwartet wird, etwa $60.3 million einzusammeln, geleitet von Samsara BioCapital mit Beteiligung von Anomaly, RA Capital, Invus, Special Situations Funds und dem Executive Chairman Mir Imran.
Rani Therapeutics (Nasdaq: RANI) أعلنت في 23 أكتوبر 2025 عن تعيين إبراهيم “Abe” باسان وفاسوديف بايلي، د.ف., في مجلس إدارتها ومغادرة أندرو فركارشون وماوليك ناناڤاتي.
وأبرزت الشركة القيمة الاستراتيجية من خطها الطبي في المراحل السريرية وشراكتها الأخيرة مع تشوجاي. كما أكملت راني صفقة طرح خاص أُعلنت سابقاً من المتوقع أن تجمع نحو $60.3 million، بقيادة Samsara BioCapital وبمشاركة Anomaly وRA Capital وInvus وSpecial Situations Funds ورئيسها التنفيذي ورئيس المجلس Mir Imran.
Rani Therapeutics（纳斯达克：RANI） 于 2025年10月23日 宣布任命 Abraham “Abe” Bassan 和 Vasudev Bailey, Ph.D. 入董事会，同时宣布 Andrew Farquharson 与 Maulik Nanavaty 的离任。
公司强调其临床阶段管线的战略价值以及与 Chugai 的最新合作。Rani 还完成了先前宣布的私募配售，预计募集约 $60.3 million，由 Samsara BioCapital 领投，Anomaly、RA Capital、Invus、Special Situations Funds 以及执行主席 Mir Imran 参与。
- Board additions: Abe Bassan and Vasudev Bailey appointed to board
- $60.3M private placement closed, led by Samsara BioCapital
- Strategic collaboration: expansion opportunities from recent Chugai collaboration
- Board turnover: Andrew Farquharson and Maulik Nanavaty stepped down
Insights
Board additions bring investor and technical experience while two directors stepped down; governance mix shifts amid strategic collaboration.
Rani appointed Abe Bassan and Vasudev Bailey, Ph.D. to its board and two directors resigned. Both new directors have investor and technical backgrounds that align with the company's stated focus on oral biologics and the collaboration with Chugai.
The changes alter board composition and skill sets; this matters for oversight of clinical programs and partnerships. Key dependencies include how actively the new directors engage with management and the board committees they join. Watch near-term governance disclosures and committee assignments over the next several months for clarity on oversight roles.
Rani closed a private placement expected to raise approximately
The financing provides a concrete cash inflow and shows continued investor support, with lead participation from Samsara BioCapital and involvement from Anomaly and others. The press release links the financing to strategic investor relationships rather than offering additional terms or dilution details.
Key watch items include any subsequent SEC filings that state final proceeds, use of proceeds, and share issuance; monitor those near-term disclosures and funding milestones within the next quarter for precise impact on operations.
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham (“Abe”) Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors.
“We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our recently announced collaboration with Chugai,” said Talat Imran, CEO of Rani Therapeutics. “Both are seasoned investors with successful track records that will bring a diverse set of skills to our Board. Abe’s deep experience as an operator in supporting therapeutics programs along with Vasudev’s expertise in biomedical engineering and emerging healthcare technology will be instrumental in unlocking the full potential of our oral delivery platform.”
Abe Bassan is currently a Partner at Samsara BioCapital, a leading biotech investment firm focused on identifying opportunities across public and private markets, where he joined in 2017 following the fund’s inception. In prior roles, he served as the Director of Program Biology at Revolution Medicines and was a project manager for multiple gene therapy programs at bluebird bio. Before bluebird, Abe was an Associate at Third Rock Ventures, where he was involved in the firm’s investment in bluebird bio and concept creation for Blueprint Medicines. He received an BA in Molecular Biology from Princeton University, and an MS in Developmental Biology from Stanford University.
Vasudev Bailey, Ph.D., is currently the General Partner of Anomaly Ventures. He also sits on the Board of Advisors for the Department of Biomedical Engineering at Johns Hopkins Medicine (since 2019) and the Board of the University of California, Irvine, since 2024. Vasudev has an extensive track record investing in health technology and therapeutics companies. Prior to his venture career, he served as the General Manager and Co-founder of GLG Institute, the world’s largest network of CEOs and CXOs, and as a Management Consultant at McKinsey & Company. Before McKinsey, he spent five years at Johns Hopkins School of Medicine developing technology for the early detection of cancer, focusing on epigenetics-based personalized chemotherapy testing. Vasudev holds a Ph.D. in Biomedical Engineering from The Johns Hopkins University School of Medicine and a BS in Biomedical Engineering with a Minor in Political Science from UC Irvine.
Rani concurrently announced the closing of its previously announced private placement that is expected to result in gross proceeds to Rani of approximately
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
About Samsara BioCapital
Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs. Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-seven years of industry experience and has an MD and a PhD in Immunology from Stanford University.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected contribution of two new directors and our ability to unlock full potential of our oral delivery platform. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “potential,” “expect,” “may,” “could” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
FAQ
Who joined the Rani Therapeutics board on October 23, 2025 (RANI)?
How much did Rani Therapeutics raise in the private placement (RANI)?
Which investors led Rani Therapeutics' private placement tied to the October 23, 2025 announcement (RANI)?
Which directors stepped down from Rani Therapeutics' board on October 23, 2025 (RANI)?
What expertise do the new RANI board members bring that could affect Rani’s strategy?
Does the October 23, 2025 RANI announcement mention collaboration with another company?
